HMHA1 Antikörper

Produktnummer ABIN7115031

Produktdetails anti-HMHA1 Antikörper

Target: HMHA1 (Histocompatibility (Minor) HA-1 (HMHA1))

Reaktivität: Human, Ratte, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HMHA1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Aufreinigung: Immunogen affinity purified

Reinheit: ≥95 % as determined by SDS-PAGE

Immunogen: histocompatibility(minor) HA-1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:2000, IHC: 1:20-1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

Haltbarkeit: 12 months

Details zu HMHA1

Target: HMHA1 (Histocompatibility (Minor) HA-1 (HMHA1))

Andere Bezeichnung: HMHA1 (HMHA1 Produkte)

Hintergrund: Synonyms:KIAA0223 Background:GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Molekulargewicht: 140-150kd

Gen-ID: 23526

UniProt: Q92619